Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Twenty-four psychotic patients were studied at two points during continuous neuroleptic treatment. Thirteen patients showed a tolerance pattern with respect to cerebrospinal fluid homovanillic acid following probenecid while 11 showed a nontolerance pattern. Patients who developed tolerance had significantly fewer symptoms and Parkinsonian side effects at approximately the fifth week of treatment.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D011618:Psychotic Disorders / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012559:Schizophrenia / Q000134:cerebrospinal fluid
D014150:Antipsychotic Agents; D010648:Phenylacetates; D006220:Haloperidol; D002746:Chlorpromazine; D006719:Homovanillic Acid